This interview is a translation of a video blog posted on Medscape France. It has been edited for clarity. Philippe Gabriel Steg, MD: Hello. Today, I would like to address a subject that many ...
June 24, 2009 — On June 17, the US Food and Drug Administration (FDA) approved a dexamethasone 0.7-mg intravitreal implant (Ozurdex, Allergan, Inc) for the treatment of macular edema after branch ...
NEW YORK, July 30 (Reuters) - Roche Holding AG's eye disease drug Lucentis proved effective in helping to improve vision in patients suffering from a condition known as central retinal vein occlusion, ...
– Additional U.S. label update across indications includes information on rare post-marketing reports of retinal vasculitis and/or retinal vascular occlusion; reporting rate is in line with other ...
New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years. However, many patients require ...
Patients with retinal vein occlusion who received Vabysmo experienced visual improvements as well as extended treatment intervals at 72 weeks, according to a study. At Angiogenesis, Exudation, and ...
COVID-19 infection may be boosting the numbers of a rare ocular condition in which vision is threatened when veins in the retina are blocked, eye specialists in Southern California report. Risk of ...
LOS ANGELES, July 2 (Reuters) - Monthly injections of Roche Holding AG's Lucentis can significantly improve sight in people with retinal vein occlusion, which leads to vision loss, according to ...
Please provide your email address to receive an email when new articles are posted on . The European Commission approved Vabysmo for the treatment of visual impairment due to macular edema secondary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results